Total Parenteral Nutrition and Decreased Dose Idarubicin Based Treatment of Acute Myeloid Leukemia in the Childhood

Yıl 2010, Cilt: 7 Sayı: 3, - 2, 01.09.2010

İbrahim Bayram Fatih Erbey Mustafa Kömür Atila Tanyeli

https://izlik.org/JA23MJ48NS

Öz

Anahtar Kelimeler

-

Total Parenteral Nutrition and Decreased Dose Idarubicin Based Treatment of Acute Myeloid Leukemia in the Childhood

https://izlik.org/JA23MJ48NS

Öz

-

Anahtar Kelimeler

-

Kaynakça

• Golub TR and Arceci RJ. Acute myelogenous leukemia. In Pizzo PA and Poplack DG: Principles and Practice of Pediatric Oncology. Lippincott Williams and Wilkins Company, Philadelphia, 4th edt. 2006; pp 591-644.
• Sasmaz I, Tanyeli A, Bayram I, et al. The results of treat- ment with idarubicin in childhood acute nonlymphoblas- tic leukemia. Turk J Pediatr 2004; 46:32-7.
• Heuvel-Elbrink MVA. Acute myeloid leukemia. In: Pinkerton R, Plowman PN, Pieters R. Paediatric oncology, third ed., Oxford University pres, 2004; 203-29.
• Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U. Duration of first remission predicts remis- sion rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 1998;12:1534-8.
• Thalhammer F, Geissler K, Jager U, et al. Duration of sec- ond complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996;72:216-22.
• Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major repro- ducible determinant of outcome. Leukemia 1988;2:403-12.
• Webb DK. Management of relapsed acute myeloid leukae- mia. Br J Haematol 1999;106:851-9.
• Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM. Outcome for children with relapsed acute myeloid leu- kaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 1999;13:25-31.
• Damon LE, Johnston LJ, Ries CA, et al. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemother Pharmacol 2004;53(6):468-74.
• Virchis A, Koh M, Rankin P, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol 2004; 124:26-32.
• Dluzniewska A, Balwierz W, Balcerska A, et al. Efficacy of idarubicin in the treatment of childhood acute non- lymphoblastic leukemia: report of Polish Pediatric Leukemia/Lymphoma Study Group, Przegl Lek 2003; 60 Suppl 5:17-21.
• O’Brien TA, Russell SJ, Vowels MR, et al. Australian and New Zealand Children’s Cancer Study Group. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children’s Cancer Study Group, Blood 2002; 100:2708-16.
• Seo T, Fukushima T, Inoue H, et al. Long-term follow-up of the clinical efficacy of chemotherapy for acute my- eloid leukemia at a single institute. J Infect Chemother 2001;7:156-62.
• Creutzig U, Berthold F, Boos J, et al. AML-BFM-Studien- Gruppe. Improved treatment results in children with AML: Results of study AML-BFM 93. Klin Padiatr 2001;213:175-85.